longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Tuoxin Pharmaceutical

301089

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -34.63, within the reasonable range, cheaper than 20.46% of the time in the past 3 years, and the industry ranks 199/221, the industry Median 23.00.

-34.63xP/E
¥21.71Stock price
¥-0.63Earnings per share
-34.63xP/E
Stock price¥21.71Earnings per share¥-0.63

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-53.93x
Typical range
-86.54x–9.01x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 23.00x
010203040

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 23.00x
0x40x80x120x160x200x
P/E ratio
Name/Symbol
688506SHBIOKIN PHARMACEUTICAL
-62.64x15.13%¥98.52B
000661SZCCHT
-82.68x588.46%¥29.15B
300255SZCSBIO
-59.84x--¥20.68B
300436SZCosunter
-66.34x--¥14.55B
300363SZPorton
-71.70x105.56%¥11.11B
000908SZCSPC Jingfeng
-258.63x--¥10.98B
301263SZT&K
-2,131.21x--¥10.08B
002099SZHISOAR
-50.61x--¥8.56B
688505SHFudan-Zhangjiang
-61.57x--¥7.77B
688176SHAsieris
-14.44x8.11%¥7.12B
000813SZDEZHAN HEALTHCARE
-19.65x--¥7.09B
600252SHZhongheng Group
-16.30x--¥7.04B
002737SZSFPM
-25.71x--¥6.68B
300267SZER-KANG
-17.25x--¥6.44B
002424SZGZBL
-49.41x--¥6.23B
600422SHKPC
-29.30x53.62%¥6.22B
000566SZHAINAN HAIYAO
-12.55x--¥6.07B
688658SHYKYY
-20.65x--¥5.54B
002082SZWBDE
-46.78x--¥5.49B
300006SZLummy
-42.65x--¥5.41B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.